Group items tagged

A recent report by the British Generic Manufacturers Association (BGMA) has shed light on ongoing supply challenges in England's generic medicines market, revealing significant issues impacting patient care. The report highlights significant challenges faced in supply of medicines as currently, 51.72 per cent of generics in short supply lack licensed alternatives, posing substantial hurdles to ensuring continuous patient care. Additionally, 39.08 per cent of affected generics are branded, indicating widespread disruptions across the market. A notable 26.44 per cent of generics experiencing shortages have been affected for over six months, highlighting persistent difficulties in supply chain management. The report indicates that 0.15 per cent of generic medicine presentations listed in the Drug Tariff are currently facing supply issues, impacting accessibility nationwide.

With Novo Nordisk's patent protection for liraglutide now expired, the UK is set to welcome the first wave of generic weight loss medicines. The British Generic Manufacturers Association (BGMA), the trade body for off-patent medicines, believes these generic versions could "provide could provide much-needed capacity to meet growing demand and alleviate shortages." Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is primarily used to treat type 2 diabetes and obesity. Novo Nordisk markets liraglutide under the brand names Victoza (for type 2 diabetes and Saxenda (for weight loss). In a statement released on 20 November 2024, the BGMA confirmed that "liraglutide's patent protection was no longer in force, marking the first time generic versions of diabetes and weight loss treatments can be available in the UK." The BGMA anticipates that at least four companies will obtain UK marketing authorisations for generics targeting type 2 diabetes and obesity. However, it remains uncertain how many will launch immediately.

With the UK General Election set for 4 July, pharmacy bodies are actively engaging with all political parties to secure support for the community pharmacy sector. They are pressing parties to address urgent issues such as pharmacy closures and medicine shortages. "The upcoming general election is a critical opportunity for us to strengthen supporters of community pharmacy in readiness for the new Parliament," said Janet Morrison, chief executive of Community Pharmacy England (CPE). She stressed the need for unity within the sector in advocating for community pharmacy and raising awareness of the issues with election candidates from all parties. As the general election approaches, CPE has called upon all political parties to support pharmacies by "introducing a long-term sustainable funding model and reviewing the medicines supply chain, including much-needed short-term relief measures."

Do you need Erlonat? Are you looking around for the best price? Oddway International is currently offering Erlonat India, manufactured by Natco Pharma. Generic Tarceva may come from other manufacturers around the world. We also have generic (erlotinib) from different manufacturers. Another alternative name for generic Tarceva is Erlonat. The strength of Erlonat is 100 mg and 150 mg tablets. For other cancer drugs, please refer to our drug categories.

The British Generic Manufacturers Association (BGMA), the representative trade association for off-patent medicines, has established a new Women's Networking Group aimed at fostering learning, networking, and career development opportunities for women in the generic and biosimilar medicines industry. Clara Carter, UK country manager of generics at Accord Healthcare, has been elected as the first chair of the group, and Elaine Holisz, strategic engagement director at Advanz, as its vice chair. Clara expressed her enthusiasm for the initiative, saying, "This is a really important association initiative which will cover a wide range of topics and issues." "At its heart, I want it to be about identifying and nurturing talent and breeding confidence in future industry leaders. We will offer mentoring and speaker opportunities among a wide range of potential activities." With over two decades of experience in the off-patent medicines industry, Clara is committed to providing participants with practical insights and guidance. Diane DiGangi Trench, Country Head UK & Ireland for Sandoz and current chair of the BGMA, highlighted the importance of the initiative, "The Women's Networking Group will be a brilliant platform to encourage new voices in our industry and I am really looking forward to participating in the planned programme."

As Prime Minister Rishi Sunak announces the forthcoming UK general election, pharmacy bodies are calling on all political parties to commit to solving the issues facing the sector. The next UK general election will be held on 4 July, Sunak announced it on Wednesday afternoon during a press conference outside 10 Downing Street. "As the election is called it's imperative that any incoming government addresses the crisis in primary care and the looming cliff edge facing pharmacies, which for millions of people are the front door to the NHS and a crucial source of frontline health care," said Paul Rees, Chief Executive of the National Pharmacy Association (NPA). Noting that the first responsibility of the government is to keep its people safe and healthy, he emphasised the importance of addressing the "deep funding gap that is pushing record numbers of pharmacies to the edge of closure and beyond, exacerbating the issues of waiting lists for GPs and hospital care."

A new study published in BMJ Open journal has revealed a significant decline in the number of general practices in England over the past decade, alongside shifts in workforce dynamics and organisational structures. Conducted by researchers from University College London (UCL) and the London School of Hygiene and Tropical Medicine (LSHTM), the study analysed data from NHS England, the Office for Health Improvement and Disparities, and the Care Quality Commission (CQC). They found that, between April 2013 and April 2023, the total number of general practices fell by 20 per cent, dropping from 8,044 to 6,419-an average loss of 178 practices per year. The decline coincided with an 11 per cent increase in the total population registered with a GP practice, which saw average practice list sizes swell by 40 per cent from 6,967 to 9,724 patients. Additionally, the number of unique practice postcodes decreased from 7163 to 5849, representing the loss of 18 per cent practice locations over this period.

Generic RU486 (mifepristone) is a trusted medical option for early pregnancy termination when combined with misoprostol. This guide explains how it works, the step-by-step process, expected results, possible side effects, and essential safety precautions. Learn what to expect before, during, and after use to make informed decisions with confidence. Explore benefits, risks, and expert insights to ensure safe and effective early pregnancy management.

The British Generic Manufacturers Association (BGMA), the trade body for off-patent medicines, has made several recommendations to alleviate medicine shortages, which not only have serious consequences for patients but also increase workloads for pharmacists. England is currently experiencing twice as many medicine shortages as it did two years ago, with some products remaining out of stock for many months, the BGMA reveals in a report, noting that "the vast majority are commonly used generic medicines." "We have witnessed the number of products facing supply challenges double in the past two years and remain at a high level since September 2023," says BGMA chief executive Mark Samuels. In its report titled 'Solutions to UK medicines shortages' published on 1 October 2024, the BGMA proposes policy changes to tackle medicine shortages, including incorporating supply chain resilience and past performance in hospital medicines tenders. "Tender scoring should include whether supply issues were reported with adequate notice. Suppliers should be informed of changes in prescribing more quickly," the report says.

Generic pharmaceutical company Brown & Burk has announced that it is "the first and the only company" to launch the new anti-smoking pill 'Varenicline' in the UK. Available through NHS stop smoking services, the daily pill has been shown to be as effective as vapes and more successful than nicotine replacement gum or patches in helping smokers quit. When combined with behavioural support, such as counselling, Varenicline was found to help one in four smokers quit for at least six months. The company told Pharmacy Business that its Varenicline 1mg and 0.5mg tablets are being distributed by Teva UK, branded with Brown & Burk's livery. Health secretary Wes Streeting recently highlighted the potential benefits of the pill, stating that its rollout could "save the NHS millions of pounds, save appointments to help other patients be seen faster, and save lives." A study by University College London suggested that Varenicline use could help over 85,000 people try to quit smoking each year, potentially preventing up to 9,500 smoking-related deaths over the next five years.

The UK Parliament is preparing for a significant reshuffling of select committee Chairs, a process that will shape the direction of parliamentary oversight for the coming term. The temporary hiatus after May 30 due to the general election on 4 July 2024, will resume as a Liberal Democrat MP will serve as the next chair of the health and social care committee (HSCC). Among the most critical positions up for election is the Chair of the Health and Social Care Select Committee, which has been allocated to the Liberal Democrats. As votes are casted to select an MP and the parliamentary landscape settles, attention is turning to what this means for the future of health policy in the UK. Liberal Dems manifesto, released during the general election that took place in July, outlined a vision for a more equitable and sustainable healthcare system, with a focus on enhancing accessibility and patient rights.

As the general election campaign heats up, major political parties - including Labour, the Conservatives, the Liberal Democrats - have released their manifestos, detailing their plans and visions for the future of community pharmacy. While the Conservative Party promises to expand Pharmacy First initiative, Labour pledges support for small businesses, with plans to overhaul the business rates system. The Liberal Democrats' election manifesto commits to developing a fairer and more sustainable long-term funding model for pharmacies. Announcing their plans recently, Prime Minister Rishi Sunak stated that they are investing in community care services to secure the future of the NHS and make healthcare more accessible. The Conservatives plan to fund these initiatives by cutting NHS managerial positions back to pre-pandemic levels and halving the government's management consultancy expenditure.

Generic Viagra Female works by enhancing the blood circulation to the female reproductive system. It is learned that decreased blood supply to the feminine reproductive system during a love making session is the reason for the decreased sensitivity of feminine reproductive organ as well as arousal issues in females. Generic Viagra Female improves the supply associated with blood to the feminine reproductive system and boosts the sensitivity in the area surrounding the feminine reproductive system.

Male impotency is an enormous issue for various men as they become old. Really in a few studies, scientists found that upsetting way of life can be likewise a variable to lead impotency. Clearly carrying on with a solid life is a compelling cure for this issue however one of the a great deal more development methodologies of taking care of this issue for men is with the backing of solutions like Viagra Generic.

Generic Bactrim is an antibiotic used for male/female bacterial & fungal infections. Buy antibiotics from our online pharmacy/drugstore without prescription.

Generic Zithromax is an antibiotic used for male/female bacterial & fungal infections. Buy antibiotics from our online pharmacy/drugstore without prescription with daily deals and coupons.

The Royal Pharmaceutical Society's (RPS) second roundtable on workforce wellbeing resulted in a series of collaborative actions to address pharmacy professionals' mental health and wellbeing challenges. The roundtable brought together key stakeholders from the pharmacy sector, including organisations like the General Pharmaceutical Council (GPhC), Community Pharmacy England (CPE), the National Pharmacy Association (NPA), and the profession's independent charity Pharmacist Support (PS). A report detailing the outcomes of the meeting was published on Friday, highlighting the key areas of discussion and the agreed-upon actions by the participants. During the roundtable, participants discussed the importance of understanding the workforce demographics, both nationally and locally, and using data to address wellbeing issues effectively. They also emphasised the need for using supportive standards set by the General Pharmaceutical Council (GPhC) and the Care Quality Commission (CQC) quality statement to support and empower pharmacists' wellbeing positively.

Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise. Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen, providing a vital treatment option for patients.

To maximise the benefits of the Pharmacy First service for patients, the NHS, and community pharmacies, Community Pharmacy England (CPE) has advised the community pharmacists to to establish a robust relationship between community pharmacies and local general practices. The news comes after several reports highlighted issues regarding GP referrals for the seven minor ailment conditions under the Pharmacy First services. According to the reports, many pharmacists claimed that "many GPs in England are not sending patients to them to be treated - and that some are refusing to participate at all in the "groundbreaking" Pharmacy First scheme". In response to foster better relationship with the GPs, CPE has said that strong local collaborations will enable general practice teams to confidently refer patients to the Pharmacy First and other community pharmacy services where appropriate. Moreover, the organisation emphasised implementation of long-term changes in practice will take time. The current focus on integrating GP referrals to Pharmacy First will likely require sustained effort over several months or longer.

Last month, the UK secured the final ratification required to join the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), marking a significant milestone in its international trade relations. The deal, set to come into force by 15 December 2024, will establish the UK as part of a free trade area spanning five continents and nearly 600 million people. With more than 99 per cent of UK goods exports to CPTPP members becoming tariff-free, the agreement is poised to boost exports and contribute to the government's goal of driving economic growth. In an exclusive interview with Pharmacy Business, Mark Samuels, chief executive of the British Generic Manufacturers Association (BGMA), discussed the impact of the UK's accession to CPTPP on the pharmaceutical sector, particularly for generic medicine manufacturers. "In many respects, the UK's accession to CPTPP will not immediately impact medicine manufacturers," Samuels said. "CPTPP had already set out the regulatory, intellectual property (IP) and market access rules in the other 11 member countries, and the UK has already worked to the standards framework in the agreement."